New hope for liver cancer: combo therapy aims to shrink tumors

NCT ID NCT07175441

Recruiting now Disease control Sponsor: Riboscience, LLC. Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 25, 2026 · Updated 26 times

Summary

This study tests a new drug (RBS2418) added to a standard immunotherapy combination (tremelimumab plus durvalumab) for people with advanced liver cancer that cannot be removed by surgery. The goal is to see if the new combo helps control the cancer longer and shrinks tumors. About 220 adults will take part, and the study is currently recruiting.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED UNRESECTABLE HEPATOCELLULAR CARCINOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Johns Hopkins
RECRUITING

Baltimore, Maryland, 21218, United States
START Dallas Fort Worth
RECRUITING

Fort Worth, Texas, 76104, United States
University of Texas Southwestern
RECRUITING

Dallas, Texas, 75390, United States
Vanderbilt-Ingram Cancer Center
RECRUITING

Nashville, Tennessee, 37232, United States

Conditions

Explore the condition pages connected to this study.

ADVANCED UNRESECTABLE HEPATOCELLULAR CARCINOMA